Back to results
US 5,393,788 AGranted
Phenylalkyl oxamides
AssigneeSmithKline Beecham Corporation
InventorsPaul E. Bender, Siegfried B. Christensen, IV, Klaus M. Esser, Cornelia J. Forster, Michael D. Ryan, Philip L. Simon
Life of this patent
Estimating the term…
Abstract
Novel oxamide derivatives are described which inhibit the production of TNF and are useful in the treatment of disease states mediated or exacerbated by TNF production. The compounds of the present invention are also useful as inhibitors of PDE IV and are therefor useful in the treatment of disease states mediated or exacerbated thereby.
Claims3
A compound which is:
- N-[2-(3-cyclopentyloxy-4-methoxyphenyl)ethyl]oxamide;
- N-[2-(3-cyclopentyloxy-4-methoxyphenyl)propyl]oxamide;
- N-[2-(3-cyclopentyloxy-4-methoxyphenyl)-2-methylpropyl]oxamide;
- N-[2-cyano-2-methyl-2-(3-cyclopentyloxy-4-methoxyphenyl)ethyl]oxamide;
- N-[2-(3-cyclopentyloxy-4-methoxyphenyl)ethyl]-N-methyloxamide;
- N-[2-(3-difluoromethoxy-4-methoxyphenyl)ethyl]oxamide;
- N-[2-(3-difluoromethoxy-4-methoxyphenyl)ethyl]oxamide;
- or
- N-[2-(3,4-didifluoromethoxyphenyl)ethyl]oxamide.
6 more elements
Dependencies are inferred from the claim text.